Table 4.

Survival data of the venetoclax plus other drugs.

Study	Treatment	Disease	ORR
Philippe Moreau	Venetoclax plus bortezomib and dexamethasone	Relapsed or refractory multiple myeloma	67%
Prof John F Seymour	Venetoclax plus rituximab	Relapsed or refractory chronic lymphocytic leukemia	82%*
Courtney D DiNardo A	Venetoclax plus decitabine	Untreated acute myeloid leukemia	65%
Courtney D DiNardo B	Venetoclax plus azacitidine	Untreated acute myeloid leukemia	59%
Courtney D DiNardo C	Venetoclax plus decitabine and posaconazole	Untreated acute myeloid leukemia	67%
Courtney D DiNardo		Untreated acute myeloid leukemia	64%
Ibrahim Aldoss	Venetoclax plus decitabine or 5-azacitidine	Relapsed or refractory acute myeloid leukemia	64%
Paula Cramer	Venetoclax plus obinutuzumab	Chronic lymphocytic leukemia	95%
Andrew H.Wei	Venetoclax plus cytarabine	Untreated acute myeloid leukemia	54% (CR)
Kerry A. Rogers	Venetoclax plus obinutuzumab and ibrutinib	Relapsed or refractory chronic lymphocytic leukemia	92%
S. de Vos	Venetoclax plus bendamustine and rituximab	Relapsed or refractory non-Hodgkin lymphoma	65%
Andrew D. Zelenetz	Ventoclax plus R/G-CHOP	Non-Hodgkin lymphoma	87.5%
Ian W. Flinn	Venetoclax plus obinutuzumab	Chronic lymphocytic leukemia	95% (R/R), 100 (1L)
Arnon P. Kater	Venetoclax plus rituximab	Relapsed or refractory chronic lymphocytic leukemia	NM

ORR, overall response rate; NM, not mentioned; CR, complete remission. *This article provided the rate of response.